New hope for Hard-to-Treat prostate cancer: targeted drug TD001 enters human trials
Disease control
Recruiting now
This study tests a new drug called TD001 in men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The drug is designed to seek out and attack cancer cells that have a specific marker (PSMA) on their surface. The main goals are to find the saf…
Phase: PHASE1, PHASE2 • Sponsor: T.O.A.D. Oncology SA • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC